For the quarter ending 2025-09-30, ATNM made $6,433K in revenue. -$5,131K in net income. Net profit margin of -79.76%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue-Revenue | - | 0 | - | - |
| Total revenue-Other Revenue | - | 0 | - | - |
| Total revenue | 90 | 0 | - | - |
| Research and development, net of reimbursements | 4,248 | 4,879 | 5,723 | 9,774 |
| General and administrative | 1,534 | 2,624 | 2,828 | 2,827 |
| Total operating expenses | 5,782 | 7,503 | 8,551 | 12,601 |
| Loss from operations | -5,692 | -7,503 | -8,551 | -12,601 |
| Interest income - net | 561 | 625 | 890 | 1,033 |
| Total other income | 561 | 625 | 890 | 1,033 |
| Net loss | -5,131 | -6,878 | -7,661 | -11,568 |
| Net loss per common share basic (in dollars per share) | -0.16 | -0.22 | -0.26 | -0.37 |
| Net loss per common share diluted (in dollars per share) | -0.16 | -0.22 | -0.26 | -0.37 |
| Weighted average common shares outstanding basic (in shares) | 31,195,891 | 31,195,891 | -15,552,166 | 31,071,297 |
| Weighted average common shares outstanding diluted (in shares) | 31,195,891 | 31,195,891 | -15,552,166 | 31,071,297 |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)